Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine

Summary

The aim of this study is to test whether the attention-enhancing effects of low-dose nicotine can be enhanced by the drug galantamine, FDA-approved for the treatment of Alzheimer's disease. This proof-of-principle study is performed in healthy non-smokers and involves two single exposures to a nicotine patch (7 mg/24 hrs) and two single exposures to galantamine (4 mg). The dose of galantamine is substantially lower than the clinical dose range of 16-24 mg/day. The hypothesis is that performance-enhancing effects of nicotine are greater in the presence of this low dose of galantamine.

Timeline

Start

2014-09

Primary completion

2017-03

Completion

2017-03

Drugs

Indications

No indication recorded.